Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revirutamide plus ADT with or without radiotherapy after radical prostatectomy in high-risk prostate cancer
ChiCTR2400082670Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rezvilutamide in prostate cancer (PCa) and prostate adenocarcinoma (2 cohorts), sponsored by Chinese PLA General Hospital. Primary endpoint: 3-year biochemical relapse-free survival rate. Started Apr 2023; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400082670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082670.